Almanac of Clinical MedicineAlmanac of Clinical MedicineАльманах клинической медицины2072-05052587-9294Moscow Regional Research and Clinical Institute (MONIKI)18110.18786/2072-0505-2014-35-101-105LECTUREЛЕКЦИЯCARDIAC GLYCOSIDES IN UP-TO-DATE CLINICAL PRACTICEСЕРДЕЧНЫЕ ГЛИКОЗИДЫ В СОВРЕМЕННОЙ КЛИНИЧЕСКОЙ ПРАКТИКЕGurevichM. A.ГуревичМ. А.
Russian Federation

MD, PhD, Professor, Internal Diseases Department, Postgraduate Medical School

д-р мед. наук, профессор, профессор кафедры терапии факультета усовершенствования врачей

magurevich@mail.ruGavrilinA. A.ГаврилинА. А.
Russian Federation

Resident physician, Internal Diseases Department, Postgraduate Medical School

клинический ординатор, кафедра терапии факультета усовершенствования врачей

Moscow Regional Research and Clinical Institute (MONIKI)ГБУЗ МО «Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского»61/2 Shchepkina ul., Moscow, 129110, Russian Federation129110, г. Москва, ул. Щепкина, 61/2, Российская Федерация15102014351011051702201617022016Copyright ©; 2014, Gurevich M.A., Gavrilin A.A.Copyright ©; 2014, Гуревич М.А., Гаврилин А.А.2014Gurevich M.A., Gavrilin A.A.Гуревич М.А., Гаврилин А.А.https://creativecommons.org/licenses/by/4.0https://almclinmed.ru/jour/article/view/181

The article reviews the use of cardiac glycosides in patients with chronic heart failure, paroxysmal tachyarrhythmia and chronic atrial fibrillation (rate control). According to the recent studies results cardiac glycosides may be substituted by angiotensin-converting enzyme inhibitors, angiotensin receptor antagonists, diuretics, calcium antagonists and beta-adrenoceptor blockers in order to decrease the risk of cardiac glycoside toxicity and, in some cases, to improve quality of life and prognosis of the patients.

В статье с  позиции доказательной медицины рассматривается применение сердечных гликозидов в  лечении хронической сердечной недостаточности, пароксизмальных тахиаритмий, а также для контроля частоты сокращений желудочков при постоянной форме фибрилляции предсердий. С  учетом результатов современных клинических исследований показана возможность замены сердечных гликозидов препаратами групп ингибиторов ангиотензинпревращающего фермента, антагонистов рецепторов ангиотензина  II, диуретиков, блокаторов кальциевых каналов, β-адреноблока- торов с целью уменьшения риска токсического действия гликозидов, а  в  некоторых случаях и улучшения прогноза заболевания и качества жизни.

cardiac glycosidesdigoxinchronic heart failureatrial fibrillationangiotensin-converting enzyme inhibitorszofenoprilverapamilesmolollandiololсердечные гликозидыдигоксинхроническая сердечная недостаточностьфибрилляция предсердийингибиторы ангиотензинпревращающего ферментазофеноприлверапамилэсмололландиолол1. Wilkins MR, Kendall MJ, Wade OL. William Withering and digitalis, 1785 to 1985. Br Med J (Clin Res Ed). 1985;290(6461):7–8.2. Российский статистический ежегодник. 2012. М.: Росстат; 2012. 786 с.(Statistical Yearbook of Russia. 2012. Moscow: Rosstat; 2012. 786 p. Russian).3. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93(9):1137–46.4. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369–429.5. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TS. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119–25.6. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A; Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P; ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14(8):803–69.7. Xie Z, Askari A. Na(+)/K(+)-ATPase as a signal transducer. Eur J Biochem. 2002;269(10): 2434–9.8. Bers DM. Calcium cycling and signaling in cardiac myocytes. Annu Rev Physiol. 2008;70: 23–49.9. Tian J, Cai T, Yuan Z, Wang H, Liu L, Haas M, Maksimova E, Huang XY, Xie ZJ. Binding of Src to Na+/K+-ATPase forms a functional signa-ling complex. Mol Biol Cell. 2006;17(1):317–26.10. Cheng JW, Rybak I. Use of digoxin for heart failure and atrial fibrillation in elderly patients. Am J Geriatr Pharmacother. 2010;8(5):419–27.11. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336(8):525–33.12. Gheorghiade M, Patel K, Filippatos G, Anker SD, van Veldhuisen DJ, Cleland JG, Metra M, Aban IB, Greene SJ, Adams KF, McMurray JJ, Ahmed A. Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur J Heart Fail. 2013;15(5):551–9.13. Butler J, Anand IS, Kuskowski MA, Rector T, Carson P, Cohn JN; Val-HeFT Investigators. Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT). Congest Heart Fail. 2010;16(5):191–5.14. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, Stijnen T, Lip GY, Witteman JC. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27(8):949–53.15. Whitbeck MG, Charnigo RJ, Khairy P, Ziada K, Bailey AL, Zegarra MM, Shah J, Morales G, Macaulay T, Sorrell VL, Campbell CL, Gurley J, Anaya P, Nasr H, Bai R, Di Biase L, Booth DC, Jondeau G, Natale A, Roy D, Smyth S, Moliterno DJ, Elayi CS. Increased mortality among patients taking digoxin – analysis from the AFFIRM study. Eur Heart J. 2013;34(20):1481–8.16. Ahmed A, Gambassi G, Weaver MT, Young JB, Wehrmacher WH, Rich MW. Effects of discontinuation of digoxin versus continuation at low serum digoxin concentrations in chronic heart failure. Am J Cardiol. 2007;100(2):280–4.17. Borghi C, Ambrosioni E; Survival of Myocardial Infarction Long-term Evaluation Study Group. Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE)-ISCHEMIA study. Am Heart J. 2007;153(3):445.e7–14.18. Borghi C, Bacchelli S, Degli Esposti D. Longterm clinical experience with zofenopril. Expert Rev Cardiovasc Ther. 2012;10(8):973–82.19. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825–33.20. Maeder MT, Rickenbacher P, Rickli H, Abbühl H, Gutmann M, Erne P, Vuilliomenet A, Peter M, Pfisterer M, Brunner-La Rocca HP; TIME-CHF Investigators. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF). Eur J Heart Fail. 2013;15(10):1148–56.21. Ulimoen SR, Enger S, Carlson J, Platonov PG, Pripp AH, Abdelnoor M, Arnesen H, Gjesdal K, Tveit A. Comparison of four single-drug regimens on ventricular rate and arrhythmia-related symptoms in patients with permanent atrial fibrillation. Am J Cardiol. 2013;111(2):225–30.22. Nagai R, Kinugawa K, Inoue H, Atarashi H, Seino Y, Yamashita T, Shimizu W, Aiba T, Kitakaze M, Sakamoto A, Ikeda T, Imai Y, Daimon T, Fujino K, Nagano T, Okamura T, Hori M; J-Land Investigators. Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction: comparison of the ultra-short-acting β1-selective blocker landiolol with digoxin (J-Land Study). Circ J. 2013;77(4):908–16.